Trevi Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 13.81 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.97B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Details
| Name | Trevi Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 34 |
| Founded | 2011 |
| Ipo Date | 2019-05-07 |
| Ceo | Jennifer Good |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 10.00 |
| Isin | US89532M1018 |
| Cusip | 89532M101 |
| Cik | 1563880 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Jennifer L. Good | Co-Founder, Chief Executive Officer, President, and Director |
| Dr. James V. Cassella Ph.D. | Chief Development Officer |
| Dr. Farrell Simon Pharm.D. | Chief Commercial Officer |
| Dr. Thomas R. Sciascia M.D. | Co-Founder and Chief Scientific Officer |
| David C. Hastings CPA | Chief Financial Officer and Principal Financial Officer |
| Christopher Galletta | Controller and Chief Accounting Officer |
| Katie McManus | Communications Manager |
Contact
| Address | 195 Church Street, 16th Floor, New Haven, Connecticut 06510, United States |
| Phone | 203 304 2499 |
| Website | https://www.trevitherapeutics.com |